Company intelligence / Profile preview

Navy Wharf

Turks and Caicos Islands

Ownership: Private
Development stage: Other

Overview

Navy Wharf, Ltd. is the IP owner and licensor of Diabetinol®—a nutraceutical product distributed by Mangoceuticals targeting the diabetes market. It retains global IP rights and is responsible for global patent defense, with product sales and commercialization responsibility held by Mangoceuticals through an exclusive licensing agreement.

Therapeutic areas: Endocrinology
Industry: Food & Nutrition

Partnerships

Mangoceuticals

Beyond the preview

Go deeper on Navy Wharf.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navy Wharf.

Explore the full profile